Navigation Links
Hard To Treat Diseases (HTDS) - CUSIP Change to Force Short Sellers To Cover
Date:9/15/2009

TORONTO, Sept. 15 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com The issuers received a certain e-mail after the market closed on September 14 2009 where amongst other things Pink Sheets claims that it has received complaints about improper promotions.

The company denies these allegations and finds these allegations disheartening and disingenuous in view of the fact that the issuer is subject to a naked short and has began a vigilant effort to have the shorts cover.

The company believes the short coverings started on September 14 as evidenced by the huge volume and over 100% raise in its share per price values in just a few short hours.

The issuer believes that a huge short position still exists on its security.

The sanctions of Pink Sheets will be namely placing a "Skull and Bones" icon and ranking on HTDS. The issuer will work vigorously to comply with Pink Sheets requests of filing a new Adequate Disclosure which according to Pink Sheets will remove the Skull and Bones rank.

The issuer has completed certain filings with Pink Sheets and an email exchange between both sides can be viewed on this link

http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=24223

HTDS and its advisors cannot and will not allow its security to be systematically erased off the books. Effective today Sept. 15, 2009 HTDS will request a new CUSIP number from its transfer agent. This "time out' which usually lasts 3-4 days to obtain the new CUSIP number will allow the company to prove to Pink Sheets that it had nothing to do with the improper "Promotion", and to complete the filings with Pink Sheets as per the Pink Sheets request see filing TAB or the direct link above.

More importantly, according to the rules, all broker dealers will have to reconcile their accounts and any short positions must be covered. This move by the HTDS management will also preserve the company equity and the last share price as recorded on close of September 14 2009.

During this 3-4 day "time out" the company will provide further updates and news so to assist shareholders with their positions and any short's not covered when the trading resumes. The issuer and its advisers feel that this is the most prudent and best course to take to protect its shareholders and its equity from the short seller's unscrupulous activities. The issuer apologizes for any inconvenience this has caused and assures its shareholders that the short term pain will be well worth the long term gain.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Particle Beam Radiation Therapy Promising But Unproven for Treating Cancer
2. Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice
3. Hard To Treat Diseases (HTDS) (H1N1) Vaccine Clinical Approval and Production
4. Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
5. Study Shows Tubal Reversal Surgery is the Best Treatment to Have More Children After a Tubal Ligation
6. Drug Offers Hope Against Tough-to-Treat Hypertension
7. Hard To Treat Diseases (HTDS) MEVAC-A Completes Tender For Bangladesh
8. New Directions in Angioedema: A Focus on Supportive Care and Treatment Options
9. Most Pharmaceutical Companies Receive Poor Grades on HIV/AIDS Drug Development Innovation, According to AIDS Treatment Activist Coalition Report Card
10. The American Legion Appeals to Congress for Compassionate Treatment of Women Veterans
11. Treating Childhood Leukemia With Fewer Side Effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
Breaking Medicine Technology: